Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/25/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/25/2021.
Displaying: 3 trials in your specialties ()
View trials across your selected specialties

Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM patientsMULTIPLE MYELOMA PATIENTS

  • Status
    Not yet recruiting
  • Phase
    Phase 2
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Iberdomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

CHU Hôtel-Dieu, 1, place Alexis Ricordeau, 44093 NANTES Cedex 1, FRANCE, Nantes, France

Brief Summary

This is a phase II study to evaluate the efficacy and safety of different doses of iberdomide continuous therapy as maintenancetreatment after transplant.

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: CC-220, Drug: Dexamethasone, Drug: Daratumumab - 16mg/kg, Drug: Bortezomib (BTZ), Drug: Carfilzomib, Drug: Daratumumab- 1800mg

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Mayo Clinic, Scottsdale, Arizona, United States

Brief Summary

This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.

Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone

  • Status
    Not yet recruiting
  • Phase
    Phase 2
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Iberdomide plus low-dose cyclophosphamide and dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Meander Medisch Centrum, Amersfoort, Netherlands

Brief Summary

Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma.